Our oncology division pioneers precision cancer therapies, advancing immunotherapy, targeted molecular treatments, and AI-driven diagnostic platforms across 34 cancer subtypes in 45 countries.
Zenth Health Sciences' Oncology Division represents one of the most comprehensive cancer research and treatment programs in the private sector. By integrating advanced genomics, artificial intelligence, and proprietary delivery technologies, we are accelerating the development of therapies that target the molecular roots of cancer with unprecedented specificity.
Our approach spans the full oncology value chain β from early discovery through molecular profiling platforms, to phase III clinical validation, and ultimately to global distribution and post-market surveillance. We operate 12 dedicated oncology research centers staffed by over 4,200 scientists, clinicians, and support personnel.
The division has established strategic partnerships with leading academic medical centers, national cancer institutes, and patient advocacy organizations to ensure our research addresses the most pressing unmet needs across solid tumors, hematologic malignancies, and rare cancers.
Our oncology program leverages six distinct therapeutic platforms, each designed to address specific mechanisms of cancer biology.
Checkpoint inhibitors, CAR-T cell therapies, cancer vaccines, and bispecific T-cell engagers designed to harness the immune system against malignant cells.
Small-molecule kinase inhibitors, antibody-drug conjugates, and PROTAC degraders targeting oncogenic drivers including EGFR, ALK, BRAF, and novel biomarkers.
CRISPR-based gene editing for tumor suppressor restoration, viral vector delivery systems, and allogeneic off-the-shelf cell therapies for broad patient access.
Proprietary AI/ML platforms for drug target identification, molecular design, patient stratification, and predictive biomarker discovery across all oncology programs.
Targeted alpha and beta-emitter radiotherapies for neuroendocrine tumors, prostate cancer, and solid tumors with expression of specific radioligand targets.
Rational combination strategies pairing immunotherapy with targeted agents, targeted therapies with other modalities, and synergistic chemotherapy regimens.
Selected assets from our oncology pipeline spanning all phases of development.
| Drug Candidate | Phase | Indication | Mechanism | Expected Readout |
|---|---|---|---|---|
|
Zenthesib
ZNT-001
|
Approved | Triple-Negative Breast Cancer | CDK4/6 + PI3K Dual Inhibitor | Ongoing |
|
Aevumcelimab
ZNT-012
|
Phase III | Non-Small Cell Lung Cancer | PD-L1 / TGF-Ξ² Bispecific Antibody | H1 2027 |
|
Zenthacel
ZNT-023
|
Phase III | Relapsed/Refractory AML | Anti-CD33 / CD123 Bispecific CAR-T | Q4 2026 |
|
Aevumatinib
ZNT-034
|
Phase II | EGFR-Mutated NSCLC (Post-Resistance) | Pan-EGFR Mutant Selective Inhibitor | Q2 2027 |
|
Zenthavir
ZNT-041
|
Phase II | Melanoma, Solid Tumors | Oncolytic HSV-1 Engineered for IL-12 | Q3 2027 |
|
Aevumacon
ZNT-048
|
Phase II | HER2-Low Breast Cancer | HER2-Targeted Antibody-Drug Conjugate | Q1 2027 |
|
Zenthradecotide
ZNT-055
|
Phase I | Metastatic Castration-Resistant Prostate Cancer | Actinium-225-PSMA Radioligand | Q4 2027 |
|
Aevumagene
ZNT-062
|
Phase I | Glioblastoma | AAV-delivered p53 Restorer Gene Therapy | Q2 2028 |
|
Zenthaprotac
ZNT-069
|
Phase I | Myeloma, Solid Tumors | IRF4-Targeted PROTAC Degrader | Q1 2028 |
Key ongoing trials across our oncology portfolio.
Phase III study of aevumcelimab + chemotherapy vs chemotherapy alone in first-line metastatic NSCLC with PD-L1 β₯50%
Phase III study of aevumacon vs trastuzumab deruxtecan in HER2-low metastatic breast cancer post-first line
Phase III study of zenthacel CAR-T in patients with relapsed/refractory AML after β₯2 prior lines of therapy
Phase II basket study of aevumatinib in EGFR-mutant NSCLC with acquired resistance to osimertinib (C797S, exon 20 ins, and others)
Phase II study of zenthavir oncolytic virus + pembrolizumab in resected stage III-IV melanoma (adjuvant setting)
World-class scientists and clinicians driving our oncology mission forward.
State-of-the-art facilities supporting discovery, development, and clinical translation worldwide.
We're actively seeking academic collaborations, co-development partnerships, and the brightest minds in oncology to join our mission.